Links between donor macrosteatosis, interleukin-33 and complement after liver transplantation

Table 5 Donor and recipient demographics for mRNA expression of grafts

Characteristic		< 30%	≥ 30%	P value
Donor
Cohort	n (%)	18	4
Age/yr	median (range)	46 (6-70)	27 (21-45)	0.13
Gender/male	n (%)	11 (61)	2 (50)	0.68
Warm ischemia time/min	Median (range)	29 (24-63)	33 (28-37)	0.93
Cold ischemia time/min	Median (range)	270 (203-296)	341 (248-422)	0.003b
Graft
Macrosteatosis	Median % (range)	2 (0-10%)	30 (30-40%)
Microsteatosis	Median % (range)	7.5 (0-80%)	45 (0-70%)	0.07
Recipient
Age/yr	Median (range)	58 (35-69)	40 (18-69)	0.07
Gender/male	n (%)	12 (67)	4 (100)	0.09
MELD-Na at transplant	Median (range)	21 (8-29)	14 (8-34)	0.66
Etiology
EtOH	n (%)	3 (17)	1 (25)
NASH	n (%)	7 (39)	3 (75)
HCC	n (%)	5 (28)
HCV	n (%)	1 (5)
Other	n (%)	2 (11)
Peak AST (Day 1-7)/(IU/L)	Median (range)	630 (212-12987)	3143 (321-9232)	0.12
Peak ALT (Day 1-7)/(IU/L)	Median (range)	494 (95-4253)	1018 (398-5002)	0.16
INR (Day 7)	Median (range)	1.1 (0.9-1.3)	1.1 (1.0-1.5)	0.45
Bilirubin (Day 7)/(mg/dL)	Median (range)	1.9 (0.6-9.6)	4.0 (1.3-16.8)	0.06
OLTHOFF EAD Index
No EAD	n (%)	16 (89)	2 (50)
EAD	n (%)	2 (11)	2 (50)	0.10

^bP < 0.01.

MELD: Model for end-stage liver disease; EtOH: Alcoholic hepatitis; NASH: Nonalcoholic steatohepatitis; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; AST: Aspartate transaminase; ALT: Alanine aminotransferase; INR: International normalized ratio; EAD: Early allograft dysfunction.